Edison Research values the Samcyprone pipe at $111M.
Not quite. The article values RXI, in its entirety (not just Samcyprone), at $111M. Which is actually damning with faint praise.
A share price of $17.06 would put a shareholder from two years ago underwater to the tune of "only" about 50%. While that's obviously better than the current 95+% underwater state for long-term shareholders, it's still ruinously bad.
If RXI can actually truly deliver on its promise, I expect a market cap of - at minimum - of $500M. But before you view me as a guru (ala the grossly incompetent / pumper biotechpicklist - aka Terry Chrisomalis) and "back up the truck", let me remind you of the lack of insider buying even with RXI's next-to-nothing market cap of less than $13M. I don't care how many options insiders already have, it's a red flag.
Look, these research articles are all too often ludicrously optimistic with numbers pulled out of thin air. Predicting precise values of R&D micro biotechs is the stuff of fantasies, best fit for the gullible.
News 
Market Data 
Discover 
